UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,553	09/02/2008	Gerold Endert	29627-221N01US	3552
35437 7590 01/20/2011 MINTZ LEVIN COHN FERRIS GLOVSKY & POPEO ONE FINANCIAL CENTER BOSTON, MA 02111			EXAMINER	
			KELLY, ROBERT M	
BOSTON, MA 02111			ART UNIT	PAPER NUMBER
			1633	
			MAIL DATE	DELIVERY MODE
			01/20/2011	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/594,553	ENDERT ET AL.	
Office Action Summary	Examiner	Art Unit	
	ROBERT M. KELLY	1633	
The MAILING DATE of this communication ap Period for Reply	opears on the cover sheet wi	th the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPLEWHICHEVER IS LONGER, FROM THE MAILING E. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by statur Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC .136(a). In no event, however, may a red d will apply and will expire SIX (6) MON te, cause the application to become AB	CATION. Sply be timely filed THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).	
Status			
1) ■ Responsive to communication(s) filed on 14 c 2a) ■ This action is FINAL . 2b) ■ This action for allowed closed in accordance with the practice under	is action is non-final. ance except for formal matt	•	
Disposition of Claims			
4) ✓ Claim(s) 46-57 is/are pending in the application 4a) Of the above claim(s) is/are withdrage 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ✓ Claim(s) 46-57 are subject to restriction and/or	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) ac Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to e drawing(s) be held in abeyan ction is required if the drawing	ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d)).
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	nts have been received. nts have been received in A ority documents have been au (PCT Rule 17.2(a)).	oplication No received in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s	ummary (PTO-413))/Mail Date ıformal Patent Application	
Paper No(s)/Mail Date	6) 🔲 Other:		

Application/Control Number: 10/594,553

Art Unit: 1633

DETAILED ACTION

Page 2

Claims 46-57 are presently pending and subject to the following restriction and/or species election requirements.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 46-53, drawn to lipsomes comprising 10-60 mole % neutral lipid, 30-50 mol % cholesterol, and either 5-30 mol % amphoteric lipids, or mixtures of cationic and anionic lipids at 50 mol % maximum, encapsulating at least one nucleotide in an aqueous interior.

Group II, claim(s) 54-57, drawn to methods of treating a mammal with a composition comprising the structure of Claim 1, and a drug.

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

U.S. Patent No. 6,649,780 to Eibl et al., teaches compositions of liposomes which are particularly preferred to be DOPE, DLPE and CHOL, with CHOL being preferred for delivery of nucleic acids (Section Entitled "Lipid Vesicle Compositions". The relative amounts lack an inventive step, as the Practitioner would optimize the amounts for their delivery, and necessarily reach the same relative amounts Applicant claims. Hence, the special technical feature is taught. Moreover, the compositions may also be utilized to solubilize membrane proteins, and the methods may be performed with other compositions for delivery. Hence, the search for one would not necessarily yield the Art and information to search and examine the other invention. Hence, there exists no general inventive concept within these claims.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Applicant is required to choose a single form of oligonucleotide from those of DNA, RNA, chemically modified DNA, or chemically modified RNA, from Claim 48.

Applicant is required to choose a single form of nucleic acid from those of antisense, RNAi, decoy, aptamer or spiegelmer, from Claims 50-52.

Applicant is required to choose a single composition of Claim 53.

The Examiner notes that election of non-commensurate species will lead to rejections for non-operability, rather than forcing consideration of more embodiments.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise require all the limitations of an allowed generic claim. Currently, the following claim(s) are generic: all claims are generic in one aspect or another.

Application/Control Number: 10/594,553 Page 4

Art Unit: 1633

REQUIREMENT FOR UNITY OF INVENTION

As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention

only or to a group of inventions so linked as to form a single general inventive concept

("requirement of unity of invention"). Where a group of inventions is claimed in a national stage

application, the requirement of unity of invention shall be fulfilled only when there is a technical

relationship among those inventions involving one or more of the same or corresponding special

technical features. The expression "special technical features" shall mean those technical features

that define a contribution which each of the claimed inventions, considered as a whole, makes

over the prior art.

The determination whether a group of inventions is so linked as to form a single general

inventive concept shall be made without regard to whether the inventions are claimed in separate

claims or as alternatives within a single claim. See 37 CFR 1.475(e).

WHEN CLAIMS ARE DIRECTED TO MULTIPLE CATEGORIES OF INVENTIONS

As provided in 37 CFR 1.475(b), a national stage application containing claims to

different categories of invention will be considered to have unity of invention if the claims are

drawn only to one of the following combinations of categories:

(1) A product and a process specially adapted for the manufacture of said product; or

(2) A product and process of use of said product; or

(3) A product, a process specially adapted for the manufacture of the said product, and a

use of the said product; or

Art Unit: 1633

(4) A process and an apparatus or means specifically designed for carrying out the said process; or

(5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

Otherwise, unity of invention might not be present. See 37 CFR 1.475(c).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species.

Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof. Applicant may submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art,

Art Unit: 1633

the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be

Page 7

amended during prosecution to require the limitations of the product claims. **Failure to do so**may result in a loss of the right to rejoinder. Further, note that the prohibition against double

patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is

withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT M. KELLY whose telephone number is (571)272-0729. The examiner can normally be reached on M-F, 9:00am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph Woitach can be reached on (571) 272-0739. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Robert M Kelly/ Primary Examiner, Art Unit 1633